7a. STRASS-2 is a Randomized Phase III of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High-Risk RPS @alegronchi Link article: https://t.co/01x7uIyegk #ASOchat

7b. Unlike STRASS-1 where neoadjuvant RT was the variable, STRASS-2 focused on neoadjuvant chemotherapy. #ASOchat

#AudioVisualAbstract : Outcomes of Distal #RectalCancer Patients Who Did Not Qualify for Watch-and-Wait: Comparison of Intersphincteric Resection Versus Abdominoperineal Resection. @Yael_Feferman @DrGarciaAguilar https://t.co/KYx6gMQVHB @csabagajdos1 @SyedAAhmad5

May Issue: Predictors of Pathologic Non-response to Neoadjuvant Approaches in Locally Advanced #RectalCancer @JyiChengNg @RichardSassun https://t.co/wf618frwb8 @csabagajdos1 @SyedAAhmad5

18s wrapped up Nationals prep today. 1st game tomorrow in Pittsburgh at 515 vs Anaheim. Thank you to our sponsor @FroJr18 for supporting the team this year #rollstorm

Our partnership with @DGlaucomflecken continues as he summarizes the final, 10-year outcomes of the CheckMate 067 trial, which investigated nivolumab plus ipilimumab in advanced melanoma. Access the article for free: https://t.co/phAdGwN6zj

New England district Champs U 18 AAA Next stop is Nationals

The basics of liver surgery @Jacobs_Med_UB, @UBSurgery, @KaleidaHealth, @UABSurgery, @UMichSurgery

https://t.co/IgPs15PmqG

@AnnSurgOncol @JamesHoweV Acknowledging it’s an uncommon manifestation, but has there been any experience with peritoneal metastases of NET? Does response to PRRT differ for those with peritoneal disease? Any role for debulking prior to PRRT? #ASOchat

“Yes, both SBNET and PNET patients had statistically significant improvements in PFS with PRRT, and OS was very close in SBNET patients (P=0.06). Smaller numbers may have contributed.” - Dr. Howe (@JamesHoweV) #ASOchat

@AMVillanoMD @AnnSurgOncol Retrospective data from the Netherlands also intriguing. Downstaging following PRRT is clearly possible, even at the tumor - vessel interface.

@AMVillanoMD @AnnSurgOncol Paging @spartelli, my go-to expert on the subject. He led the NEOLUPANET phase 2 trial. Preoperative PRRT certainly safe and can be done but will it improve overall outcomes as well as resectability? With the ORR seen, certainly something to think about

Today, we will discuss PRRT for GEP-NETs from a surgeon’s perspective. What is the surgeon’s role prior to PRRT for patients with gastroenteropancreatic NETs? #ASOchat

📢 Join us for the next #ASOChat! Awesome lineup of special guests to discuss PRRT, surgical debulking, and more! Looking forward to many jumping in to chat 💯 @TraceyPuMD @Csabagajdos1 @DrSabha @SchultzKurt @SyedAAhmad5 @SocSurgOnc

January Issue: Minimally Invasive Surgery: Is It a Risk Factor for Postoperative #PeritonealMetastasis in pT4 #ColonCancer ? https://t.co/A2nXtmaCZe @jeffreyfarma @SyedAAhmad5

Whipple with portal vein reconstruction @Jacobs_Med_UB @KaleidaHealth @UBSurgery @UMichSurgery @UABSurgery @DrZaaroura

Mid bile duct resection @KaleidaHealth @Jacobs_Med_UB @UBSurgery @UABSurgery @UMichSurgery @DrZaaroura

Save the date. #ASOchat

For discussion on the next #ASOchat : Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors https://t.co/6KNe88Fax1 Thursday, 1/30, 6:00 PM EST